Măsuri recomandate în vederea reducerii impactului pandemiei COVID-19 asupra pacienților oncologici și asupra serviciilor de oncologie.

Click aici

Dear Oncology Colleagues of Romania,

 

This is an invitation to participate in a research study being conducted in conjunction with the World Health Organization (WHO) to help determine which oncology medications are deemed most essential to cancer care. 

 

The Essential Medicines List (EML) is produced by the World Health Organization. The aim of this list is to provide a consolidated list of high value medications on which national formularies can be based. However, little is known on the degree to which the EML list itself actually correlates to the views of front-line healthcare providers in nations around the world especially in the field of Oncology especially with regards to the medications they view as absolutely essential to the practice of Oncology.

 

This survey is designed to discover the ten cancer therapeutics that front-line cancer physicians truly deem to be most essential and to discover whether there are any notable omissions from the EML list as it stands that should be re-visited. 

 

If you agree to take part in this survey by clicking the survey link at the bottom of the page you will be directed to our on-line survey. The survey should take you less than 10 minutes to complete. There is no known risk to taking the survey. The information collected will be entirely anonymous and there will be no way to identify you after the survey is complete. There are no direct benefits to you as a participant. Study results will help to inform future WHO Essential Medicine List policy decisions going forward.  The results of this survey will be published in an academic peer reviewed journal. The study data will be archived in an electronic repository indefinitely after 5 years.

 

Participation is voluntary. You have not waived any legal rights by your participation. Non-submitted data will not be collected. After the survey is submitted, it cannot be withdrawn. You do not have to answer any questions you don’t want to. You can stop participating at any time without penalty. Please keep a copy of this letter of intent for your records.  

 

For ethics concerns please contact the Queen’s University Health Sciences and Affiliated Teaching Hospitals Research Ethics Board (HSREB) at 1-844-535-2988 (Toll free in North America) or hsreb@queensu.ca. For research conducted outside of North America use: 1-613-533-2988. If non-English speaking participants wish to contact the Chair for ethics concerns, translation assistance may be necessary, as the REB Chairs communicate in English only. The HSREB may require access to study-related records to monitor the ethical conduct of the research itself.

 

If you have any questions about the research, please contact Prof Christopher Booth at booth@queensu.ca

 

This study has been reviewed for ethical compliance by the Queen’s University Health Sciences and Affiliated Teaching Hospitals Research Ethics Board.

 

For on-line consent:

By clicking below, I am verifying that: I have read the Letter of Information and I consent to participate in this research study:

Thank you for supporting this effort in global cancer policy.

Sincerely,

Christopher Booth MD FRCPC

Professor of Medical Oncology

Member, WHO Cancer Medicines Working Group

Canada Research Chair in Population Cancer Care

Clinician-Scientist, Division of Medical Oncology

Queen’s University, Kingston, Canada

Email: booth@queensu.ca